Aanjaneya Lifecare, a Rs.300 crore plus Mumbai based pharma company, has reported impressive performance during the second quarter ended September 2011. Its net profit went up by 45.9 per cent to Rs.12.37 crore from Rs.8.48 crore in the corresponding period of last year. Its net sales moved up by 38.8 per cent to Rs.110.98 crore from Rs.79.95 crore. With significant in profits, its earnings per share after considering the rise in equity capital to Rs.12.58 crore from Rs.7.58 crore in the previous period, worked out to Rs.11.17 as against Rs.11.16 in the last period.

For the first half ended September 2011, the company's net sales improved to Rs.211.23 crore from Rs.135.25 crore , a growth of 56.2 per cent. Its net profit also moved up by 51 per cent to Rs.23.65 crore from Rs.15.67 crore. EBDITA increased by 56.6 per cent to Rs.46.94 crore from Rs.29.98 crore in the similar period of last year. As against the equity capital of Rs.12.58 crore its reserves & surplus stood at Rs.262.46 crore.

Dr Kannan Vishwanath, vice-chairman and managing director, said, “We are really happy to see that India continues its growth in pharma business. Our company has showed an impressive growth in the current year and we promise our investors and stakeholdes that we will continue to do the same in future. We are convinced that taking this growth forward, we will be able to achieve our long term vision of dominating our product categories worldwide. The impact of the new developments would be felt in the next quarter and we expect further consolidation of our new revenue and profits.”

The company raised Rs.117 crore its IPO and the funds are being used to built new capacities along with the refurbishing of R&D centre. The company is expanding its operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operations in branded generics segment. Out of total IPO proceedings, the company has spend Rs.77.50 crore on new facilities till the end of September 2011.